Immutep reports final data from phase one study of LAG-3 Therapy

June 8, 2021 Australian Biotech

This is a preview of subscriber content

Subscribe now to continue reading.

Immutep (ASX:IMM), a company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, has announced what it describes as "encouraging final data" from its phase one INSIGHT-004 study. …

Subscribe now to continue reading.

Latest Video

What if the system put people first? Imagining the institution we don’t have
November 20, 2025 - Latest News
Vertex secures TGA approval for next-generation cystic fibrosis therapy
November 19, 2025 - Latest News
If the system properly applied results in harm, then the problem is worse than we think
November 20, 2025 - Latest News
Silence in response to unethical processes and outcomes is itself unethical
November 20, 2025 - Latest News
Ronak Patel appointed to lead Alcon’s commercial management for vision care
November 20, 2025 - Latest News

Immutep reports final data from phase one study of LAG-3 Therapy

This is a preview of subscriber content

Latest Video

Most Read

What if the system put people first? Imagining the institution we don’t have

Vertex secures TGA approval for next-generation cystic fibrosis therapy

If the system properly applied results in harm, then the problem is worse than we think

Silence in response to unethical processes and outcomes is itself unethical

Ronak Patel appointed to lead Alcon’s commercial management for vision care

New Stories

Mesoblast to launch pivotal adult trial for cell therapy in severe steroid-refractory GVHD

Syntara launches Phase 2 trial aiming to teduce transfusion burden in myelodysplastic syndromes

Alterity Therapeutics chairman reflects on two decades of progress as company enters new era

Treasurer blocks US takeover of Mayne Pharma on national interest grounds

If the system properly applied results in harm, then the problem is worse than we think

Silence in response to unethical processes and outcomes is itself unethical

New analysis shows Telix's TLX250-CDx could change management of renal masses

Sign In

Immutep reports final data from phase one study of LAG-3 Therapy

This is a preview of subscriber content

Latest Video

Most Read

What if the system put people first? Imagining the institution we don’t have

Vertex secures TGA approval for next-generation cystic fibrosis therapy

If the system properly applied results in harm, then the problem is worse than we think

Silence in response to unethical processes and outcomes is itself unethical

Ronak Patel appointed to lead Alcon’s commercial management for vision care

Follow Us

New Stories

Mesoblast to launch pivotal adult trial for cell therapy in severe steroid-refractory GVHD

Syntara launches Phase 2 trial aiming to teduce transfusion burden in myelodysplastic syndromes

Alterity Therapeutics chairman reflects on two decades of progress as company enters new era

Treasurer blocks US takeover of Mayne Pharma on national interest grounds

If the system properly applied results in harm, then the problem is worse than we think

Silence in response to unethical processes and outcomes is itself unethical

New analysis shows Telix's TLX250-CDx could change management of renal masses